Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: Updated summary

Current Medical Research and Opinion

Volumn 23, Issue 7, 2007, Pages 1715-1732

  Spatafora, Sebastiano ^a   Conti, Giario ^b   Perachino, Massimo ^c   Casarico, Antonio ^d   Mazzi, Giorgio ^a   Pappagallo, Giovanni Luigi ^e  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c Ospedale S Spirito Casale Monferrato   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e PF Calvi Hospital   (Italy)

Author keywords

Diagnosis; Drug therapy; Lower urinary tract symptoms; Practice guidelines; Prostatic diseases; Prostatic hyperplasia; Surgery

Indexed keywords

ALFUZOSIN; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

CLINICAL TRIAL; COMORBIDITY; DRUG MECHANISM; ECHOGRAPHY; ECONOMIC ASPECT; EJACULATION DISORDER; EVIDENCE BASED PRACTICE; GYNECOMASTIA; HUMAN; LIBIDO; LOWER URINARY TRACT SYMPTOM; MEDICAL LITERATURE; MICROWAVE THERAPY; PRACTICE GUIDELINE; PREVALENCE; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; TRANSURETHRAL RESECTION; URINARY TRACT DISEASE;

ADULT; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; ITALY; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; URINATION DISORDERS;

EID: 34547152167     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210534     Document Type: Review

References (141)

1. Associazione Urologi Italiani (AURO.it). Guideline on benign prostatic hyperplasia 2004. Available at: www.auro.it/lg8.pdf (last accessed 9 May 2007)
2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
3. Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003;139:493-8
4. McConnell JD, Roehrborn CG, Bautista OM, et al.; for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. M-TOPS: the long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New Engl J Med 2003;349:2387-98
5. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49
6. Spatafora S, Canepa G, Migliari R, et al.; for AURO.it Cooperative Group. Diagnostic procedures by Italian general practitioners in response to lower urinary tract symptoms in male patients: a prospective study. Curr Med Res Opin 2004;20:713-21
7. Vavassori I, Hurle R, Vismara A, et al. Holmium laser enucleation of the prostate combined with mechanical morcellation: 2 years of experience with 196 patients. J Endourol 2004;18: 109-12
8. Emberton M, Andriole GL, de la Rosette J, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003;61:267-73
9. Roehrborn CG, Malice M, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001;58:210-6
10. Wright EJ, Fang J, Metter EJ, et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 2002;167:2484-7
11. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo [PLESS Study Group]. Urology 1999;54:662-9
12. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res 2000;12:305-11
13. Boyle P, Robertson C, Mazzetta C, et al.; for the UrEpik Study Group. The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. Br J Urol Int 2003;92:719-25
14. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005;29:310-6
15. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562-8
16. Michel MC, Heemann U, Schumacher H, et al. Association of hypertension of symptoms of benign prostatic hyperplasia. J Urol 2004;172:1390-3
17. St. Sauver JL, Jacobson DJ, Girman CJ, et al. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J Urol 2006;175:1018-22
18. Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006;175:1422-7
19. Shabsigh R, Perelman MA, Lockhart DC, et al. Health issues of men: prevalence and correlates of erectile dysfunction. J Urol 2005;174:662-7
20. Ponholzer A, Temml C, Obermayr R, et al. The association between lower urinary tract symptoms and erectile dysfunction. Urology 2004;64:772-6
21. Paick SH, Meehan A, Lee M, et al. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the Proscar long-term efficacy and safety study. J Urol 2005;173:903-7
22. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935-44
23. Collins MM, Meigs JB, Barry MJ, et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002;167:1363-6
24. Koskimaki J, Hakama M, Huhtala H, Tammela TLJ. Association of non-urological diseases with lower urinary tract symptoms. Scand J Urol Nephrol 2001;35:377-81
25. Gades NM, Jacobson DJ, Girman CJ, et al. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. Br J Urol Int 2005;95:549-53
26. Koseoglu H, Aslan G, Ozdemir I, Esen A. Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy. Urology 2006;67:1188-92
27. Badia X, Garcia-Losa M, Dal-Re R. Ten-language translation and harmonization of the International Prostate Symptom Score: developing a methodology for multinational clinical trials. Eur Urol 1997;31:129-40
28. Potter SR, Horniger W, Tinzl M, et al. Age, prostate-specific antigen and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001;57:1100-4
29. Roehrborn CG, Sech S, Montoya J, et al. Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology 2001;57: 1087-92
30. Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen study. Eur Urol 2004;46:753-9
31. Loeb S, Han M, Roehl KA, et al. Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography. J Urol 2005;173:63-5
32. Mohr DN, Offord KP, Owen RA, Melton 3rd U. Asymptomatic microhematuria and urologic disease. A population-based study. J Am Med Assoc 1986;256:224-9
33. American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH), 2003. Available at: www.auanet.org/guidelines/bph. cfm [last accessed 9 May 2007]
34. Rule AD, Jacobson DJ, Roberts RO, et al. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int 2005;67:2376-82
35. Ponholzer A, Temml C, Obermayr RP, et al. The association between lower urinary tract symptoms and renal function in men: a cross-sectional and 5-year longitudinal analysis. J Urol 2006;175:1398-402
36. Mochtar CA, Kiemeney LALM, van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003;44:695-700
37. Mochtar CA, Kiemeney LALM, van Riemsdijk MM, et al. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J Urol 2006;175:213-6
38. Yuen JS, Ngiap JT, Cheng CW, Foo KT. Effects of bladder volume on transabdominal ultrasound measurements of intravesical prostatic protrusion and volume. Int J Urol 2002;9:225-9
39. Huang Foen Chung JWNC, de Vries SH, Raaijmakers R, et al. Prostate volume ultrasonography: the influence of transabdominal versus transrectal approach, device type and operator. Eur Urol 2004;46:352-6
40. Eri LM, Thomassen H, Brennhovd B, Haheim LL. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer P D 2002;5:273-8
41. Miyashita H, Kojima M, Miki T. Ultrasonic measurement of bladder weight as a possible predictor of acute urinary retention in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Ultrasound Med Biol 2002;28:985-90
42. McClennan BL. Diagnostic imaging evaluation of benign prostatic hyperplasia. Urology 1979;14:292-4
43. Homma Y, Ando T, Yoshida M, et al. Voiding and incontinence frequencies: variability of diary data and required diary length. Neurourol Urodyn 2002;21:204-9
44. Fitzgerald MP, Butler N, Shott S, Brubaker L. Bother arising from urinary frequency in women. Neurourol Urodyn 2002;21:36-40
45. Schick E, Jolivet-Tremblay M, Dupont C, et al. Frequency-volume chart: the minimum number of days required to obtain reliable results. Neurourol Urodyn 2003;22:92-6
46. Roberts RO, Jacobsen SJ, Jacobson DJ, et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000;163:107-13
47. Wei JT, Schottenfeld D, Cooper K, et al. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol 2001;165:1521-5
48. Schafer W, Abrams P, Liao L, et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21:261-74
49. Reynard JM, Yang Q, Donovan JL, et al. The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998;82:619-23
50. Van Melick HHE, Van Venrooij GEPM, Eckhardt MD, Boon TA. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: Urodynamic effects. J Urol 2002;168:1058-62
51. Griffiths CJ, Harding C, Blake C, et al. A nomogram to classify men with lower urinary tract symptoms using urine flow and noninvasive measurement of bladder pressure. J Urol 2005;174:1323-6
52. Kessler TM, Gerber R, Burkhard FC, et al. Ultrasound assessment of detrusor thickness in men - can it predict bladder outlet obstruction and replace pressure-flow study? J Urol 2006;175:2170-3
53. Bruskewitz RC, Reda DJ, Wasson JH, et al. Testing to predict outcome after transurethral resection of the prostate. J Urol 1997;157:1304-8
54. De la Rosette JJ, Alivizatos G, Madersbacher S, et al.; for the European Association of Urology. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001;40:256-63
55. Chatelain C, Denis L, Foo K, et al. Proceedings of the fifth international consultation on benign prostatic hyperplasia. United Kingdom: Health Publications Ltd.; 2001
56. Knutson T, Schafer W, Fall M, et al. Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting? - a four-year follow-up study. Scand J Urol Nephrol 2001;35:463-9
57. Djavan B, Fong YK, Harik M, et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 2004;64:1144-8
58. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. Br J Urol Int 2003;91:41-4
59. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13
60. Kirby RS, Andersen M, Gratzke P, et al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin- gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. Br J Urol Int 2001;87:192-200
61. DeMey C, Michel MC, Mc Ewen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal ortostatic stress testing. Eur Urol 1998;33:481-8
62. Kirby RS, Roherborn C, Boyle P, et al.; for the PREDICT Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26
63. Roehrborn CG, van Kerrebroek P, Nordling J. Safety and efficacy of alfuzosin 10mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo controlled studies. Br J Urol Int 2003;92:257-61
64. Lepor H; for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892-900
65. Höfner K, Claes H, De Reijke TM, et al. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:335-41
66. Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2003;(1):CD002081
67. Roehrborn CG. Alfuzosin 10mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. Br J Urol Int 2006;97:734-41
68. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. Br J Urol Int 2005;95:1006-12
69. American Urological Association. AUA responds to advisory on alpha-blocker therapy and intraoperative floppy iris syndrome. Media release, 22 August 2006. Available at: www.ascrs.org/press_releases/upload/ AUA_IFIS_statement.doc [last accessed 9 May 2007]
70. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2α-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172:1935-40
71. Giuliano F, Kaplan SA, Cabanis MJ, Astruc B. Hemodynamic interaction study between the alpha-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle aged healthy male subjects. Urology 2006;67:1199-204
72. Gormley GJ, Stoner E, Bruskewitz RC, et al.; for the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. J Urol 2002; 167:1102-7
73. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study [PROWESS Study Group]. Urology 1998;51:677-86
74. Roehrborn CG, Bruskewitz R, Nickel GC, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes [The PLESS Study Group]. Eur Urol 2000;37:528-36
75. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 2002;2:14
76. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia [PLESS Study Group]. Proscar Long-term Efficacy and Safety Study. Urology 1999;54:670-8
77. Hudson PB, Boake R, Trachtenberg J, et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years [The North American Finasteride Study Group]. Urology 1999;53:690-5
78. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial [PLESS Study Group]. Proscar Long-term Efficacy and Safety Study. Urology 1998;52:195-201
79. Roehrborn CG, Boyle P, Nickel JC, et al.; for ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41
80. Wessels H, Roy J, Bannow J, et al.; for the PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61:579-84
81. Andriole GL, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8
82. Debruyne F, Barkin J, van Erps P, et al.; on behalf of the ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46: 488-95
83. Slawin KM, Kattan MW, Roehrborn CG, Wilson T. Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. Urology 2006;67:84-8
84. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5α-reductase inhibitor dutasteride. J Urol 2006;175:1657-62
85. Donohue JF, Hayne D, Karnik U, et al. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. Br J Urol Int 2005;96: 1319-22
86. Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia [European ALFIN Study Group]. Eur Urol 1998;34:169-75
87. Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 mL or greater. J Urol 2006;175:217-21
88. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;(3): CD001423
89. Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;(1):CD001044
90. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002;41: 497-506
91. Willetts KE, Clements MS, Champion S, et al. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003;92:267-70
92. Denis L, Pagano F, Nonis A, et al. Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH. Prostate 1998;37: 246-52
93. Eri LM, Tveter KJ. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. J Urol 1994;152: 448-52
94. Debruyne F, Boyle P, Calais de Silva F, et al. Evaluation of the clincial benefit of permixon and tamsulosin in severe BPH patients - PERMAL study subset analysis. Eur Urol 2004;45:773-9
95. Boyle P, Robertson C, Lowe F, Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. Br J Urol Int 2004;93:751-6
96. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. New Engl J Med 2006;354: 557-66
97. Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.: a randomized prospective trial of 120 patients. J Urol 2002;168:1465-9
98. Tubaro A, Carter S, Hind A, et al. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001;166: 172-6
99. Gacci M, Bartoletti R, Figlioli S, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. Br J Urol Int 2003;91:196-200
100. Shalev M, Richter S, Kessler O, et al. Long-term incidence of acute myocardial infarction after open and transurethral resection of the prostate for benign prostatic hyperplasia. J Urol 1999;161:491-3
101. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? Br J Urol Int 1999;83:227-37
102. Van Venrooij GEPM, van Melick HHE, Eckhardt MD, Boon TA. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate J Urol 2002;168:605-9
103. Scholtz M, Luftenegger W, Harmuth H, et al. Single-dose antibiotic prophylaxis in transurethral resection of the prostate: a prospective randomized trial. Br J Urol Int 1998;81:827-9
104. Bell CR, Murdock PJ, Pasi KJ, Morgan RJ. Thrombotic risk factors associated with transurethral prostatectomy. Br J Urol Int 1999;83:984-9
105. Sidney S, Queensberry Jr CP, Sadler MC, et al. Reoperation and mortality after surgical treatment of benign prostatic hypertrophy in a large prepaid medical care program. Med Care 1992;30:117-25
106. Semmens JB, Wisniewski ZS, Bass AJ, et al. Trends in repeat prostatectomy after surgery for benign prostate disease: application of record linkage to healthcare outcomes. Br J Urol Int 1999;84:972-5
107. Yang Q, Peters J, Donovan JL, et al. Transurethral incision compared with transurethral resection of the prostate for bladder oudet obstruction: a systematic review and meta-analysis of randomized controlled trials. J Urol 2001;165:1526-32
108. Hammadeh MY, Madaan S, Hines J, Philp T. Five-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology 2003;61:1166-71
109. Gallucci M, Puppo P, Perachino M, et al. Transurethral electrovaporization of the prostate vs. transurethral resection. Results of a multicentric, randomized clinical study on 150 patients. Eur Urol 1998;33:359-64
110. Hoffman RM, MacDonald R, Slaton JW, Wilt TJ. Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. J Urol 2003;169:210-5
111. Van Melick HH, van Venrooij GE, Eckhardt MD, Boon TA. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: analysis of subjective changes, morbidity and mortality. J Urol 2003;169:1411-6
112. Hon NH, Brathwaite D, Hussain Z, et al. A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term follow-up. J Urol 2006;176:205-9
113. Tefleki A, Muslumanoglu A, Baykal M, et al. A hybrid technique using bipolar energy in transurethral prostate surgery: a prospective, randomized comparison. J Urol 2005;174: 1339-43
114. Van Melick HH, van Venrooji GE, Boon TA. Long-term follow-up after transurethral resection of the prostate, contact laser prostatectomy, and electrovaporization. Urology 2003;62: 1029-34
115. Nuhoglu B, Ayyildiz A, Fidan V, et al. Transurethral electrovaporization of the prostate: is it any better than standard transurethral prostatectomy? 5-year follow-up. J Endourol 2005;19:79-82
116. Kuntz RM, Ahyai S, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J Urol 2004;172:1012-6
117. Montorsi F, Naspro R, Salonia A, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol 2004;172: 1926-9
118. Gupta N, Kumar SR, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of > 40 g. Br J Urol Int 2006;97: 85-9
119. Kuntz RM, Lehrich K, Ahyai S. Transurethral holmium laser enucleation of the prostate compared with transvesical open prostatectomy: 18-month follow-up of a randomized trial. J Endourol 2004;18:189-91
120. Leliefeld HHJ, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. Br J Urol Int 2002;89:208-13
121. Brookes ST, Donovan JL, Peters TJ, et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. Br Med J 2002;324: 1059-64
122. Arai Y, Aoki Y, Okubo K, et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol 2000;164: 1206-11
123. Donovan JL, Peters TJ, Neal DE, et al. A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: the ClasP Study. J Urol 2000;164:65-70
124. Roehrborn CG. Standard surgical interventions: TURP/TUIP/OPSU. In: Kirby R, McConnell J, Fitzpatrick J, et al., editors. Textbook of benign prostatic hyperplasia. Oxford: ISIS Medical Media; 1996. p. 341-78
125. Martenson AC, De la Rosette JJMCH. Interstitial laser coagulation in the treatment of benign prostatic hyperplasia using a diode laser system: results of an evolving technology. Prostate Cancer Prostatic Dis 1999;2:148-54
126. Sarica K, Alkan E, Lüleci H, Taşci I. Photoselective vaporization of the enlarged prostate with KTP laser: long-term results in 240 patients. J Endourol 2005;19:1199-202
127. Te AE, Malloy TR, Stein BS, et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 2004;172:1404-8
128. Reich O, Bachmann A, Siebels M, et al. High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol 2005;173:158-60
129. Floratos DL, Kiemeney LA, Rossi C, et al. Long-term follow-up of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 2001;165: 1533-8
130. Djavan B, Seitz C, Roehrborn CG, et al. Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. Urology 2001;57:66-70
131. Francisca EA, d'Ancona FC, Hendriks JC, et al. A randomized study comparing high-energy TUMT to TURP: quality-of-life results. Eur Urol 2000;38:569-75
132. Wagrell L, Schelin S, Nordling J, et al. Three-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 2004;64:698-702
133. Gravas S, Laguna P, Ehrnebo M, et al. Seeking evidence that cell kill guided thermotherapy gives results non inferior to those of transurethral prostate resection: results of a pooled analysis of 3 studies of feedback transurethral microwave thermotherapy, J Urol 2005;174:1002-6
134. Trock BJ, Brotzman M, Utz WJ, et al. Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years. Urology 2004;63:716-21
135. Zlotta AR, Giannakopoulos X, Maehlum O, et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003;44:89-93
136. Schatzl G, Madersbacher S, Djavan B, et al. Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options. Eur Urol 2000;37:695-701
137. Roehrborn CG, Issa MM, Bruskewitz RC, et al. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology 1998;51:415-21
138. Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004;171:2336-40
139. Perry MJ, Roodhouse AJ, Gidlow AB, et al. Thermo-expandable intraprostatic stents in bladder outlet obstruction: an 8-year study. Br J Urol Int 2002;90:216-23
140. Madersbacher S, Schatzl G, Djavan B, et al. Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol 2000;37:687-94
141. Van Dijck MM, Mochtar CA, Wijkstra H, et al. The bell-shaped nitinol prostatic stent in the treatment of lower urinary tract symptoms: experience in 108 patients. Eur Urol 2006;49:353-9